Market Intelligence, Clinical Progress, and High-Purity Reagents for Lymphoma & Solid Tumor Epigenetic Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EZH2 Y641F drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Protein (SET Domain) | EZH2 Y641F Recombinant Protein, Sequence Verified, High Purity (>95%), Endotoxin <1EU/μg. Activity-Ready for HMTase assays. | View EZH2 Y641F Products |
| Wildtype Control | EZH2 WT Recombinant Protein (SET Domain), HEK293 Expressed. For selectivity screening and comparative kinetic studies. | View EZH2 Products |
| Complex Partner: EED | EED Recombinant Protein, PRC2 core component required for EZH2 stimulation. High Purity (>95%). | View EED Products |
| Complex Partner: SUZ12 | SUZ12 Recombinant Protein, PRC2 scaffolding protein. Sequence Verified for complex reconstitution assays. | View SUZ12 Products |
| Gene Delivery | EZH2 Y641F Promise-ORF / Lentivirus, Full-length ORF with Y641F mutation for stable cell line construction in lymphoma models. | View EZH2 Y641F Products |
| Validator | EZH2 siRNA Set, For knockdown specificity verification and target engagement confirmation. | View EZH2 Products |
| Related Target: EZH1 | EZH1 Recombinant Protein, Compensatory PRC2 catalytic subunit; dual EZH2/EZH1 inhibition strategy. | View EZH1 Products |
| Related Target: BCL2 | BCL2 Recombinant Protein, Downstream survival pathway; frequent co-alteration in EZH2-mutant follicular lymphoma. | View BCL2 Products |
| Benchmark Ab | Anti-EZH2 Recombinant Antibody, Detection control for Western Blot, IP, and IF validation. | View EZH2 Y641F Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs WT Selectivity Screening | Matched Pair Available: EZH2 Y641F & Wildtype proteins with identical tags (His or GST), expressed in HEK293 for consistent post-translational modifications. |
| PRC2 Complex Activity Reconstitution | Individual High-Purity Components (EZH2, EED, SUZ12) allowing flexible stoichiometry vs. pre-formed complex options. Multi-subunit co-expression preserving native active conformation. |
| Histone Substrate Specificity (H3K27me2 vs me3) | High-specificity recombinant histone H3 proteins available for quantitative methylation state detection assays. |
| Cellular Model Construction | Lentiviral particles with EZH2 Y641F mutation for stable integration into lymphoma cell lines (Karpas-422, WSU-DLCL2). |
| Lack of Assay Standards | Research-grade Anti-EZH2 antibodies and paired mutant/WT reference proteins included as assay standards. Validated siRNA included for specificity checks. |
| Methyltransferase Subfamily Counter-Screening | Homolog panel including EZH1, SUV39H1, and SETD7 strictly verified by mass spec for selectivity assays. |
Live EZH2 Y641F R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The landscape for EZH2 Y641F-targeted therapeutics is transitioning from first-generation inhibitors to next-generation mutant-selective and combination approaches. While Tazemetostat (Epizyme/Ipsen) gained FDA approval for EZH2-mutant follicular lymphoma, clinical resistance mechanisms and suboptimal WT vs mutant selectivity have driven the industry toward second-generation inhibitors (Valemetostat, HH2853) and PROTAC degraders. The next wave of R&D focuses on overcoming acquired resistance mutations (e.g., A677G, I687V) and synthetic lethal combinations with BCL2 inhibitors (Venetoclax) in follicular lymphoma and DLBCL settings. As first-generation therapies reach the clinic for lymphomas, major players are shifting focus from traditional competitive inhibitors to targeted protein degradation (PROTACs) and allosteric modulation (e.g., targeting EED). The Y641F gain-of-function mutation alters substrate specificity: wild-type EZH2 converts H3K27me2 to me3, while Y641F mutants lose me3 catalytic capacity and accumulate me2. This requires assays that quantitatively distinguish H3K27me2 vs. me3 generation, rather than generic methylation activity detection. Ideal next-generation inhibitors should exhibit at least 10-fold selectivity for Y641F over wild-type to reduce off-target toxicity (e.g., hematopoietic stem cell suppression). TarMart's matched mutant/WT protein pairs, modular PRC2 components, and lentiviral delivery tools enable precise selectivity profiling, complex reconstitution, and cellular model construction to meet these challenges.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (1st Gen) | Epizyme/Ipsen (Tazemetostat) | Follicular Lymphoma (EZH2 mutant) | WT vs Y641F Selectivity Assay (Need matched mutant/WT proteins) |
| Small Molecule (Dual EZH1/2) | Daiichi Sankyo (Valemetostat) | Adult T-cell Leukemia, B-cell Lymphomas | Substrate Specificity Assay (H3K27me2 accumulation detection) |
| PROTAC Degrader | Pfizer, Constellation Bio, Dialectic Therapeutics | Solid Tumors, DLBCL | Cellular Target Engagement (Need Lentivirus for stable mutant cell lines); Ternary Complex Validation (Need High-Purity Proteins) |
| Combination (EZH2i + BCL2i) | Roche, AbbVie | Refractory FL | Pathway Panel Screening (Need BCL2 + EZH2 proteins for synergy studies) |
| Allosteric Inhibitors (EED focus) | Novartis | Hematological Malignancies | Complex Integrity Assays (Need Co-expressed Complex) |
Related Targets
- EED: PRC2 allosteric regulatory subunit. EED inhibitors (e.g., A-395) synergize with EZH2 inhibition. TarMart provides full-length EED protein for allosteric site screening.
- SUZ12: PRC2 scaffold protein; loss-of-function mutations can compensate for EZH2 inhibition. TarMart SUZ12 recombinant protein supports complex assembly studies.
- BCL2: Frequent co-alteration in EZH2-mutant FL. EZH2i + BCL2i (Venetoclax) combinations overcome monotherapy resistance. TarMart BCL2 protein enables biochemical synergy screening.
- EZH1: Homolog of EZH2; used as off-target toxicity control or for dual EZH1/2 inhibitor development.
Key Molecular Differentiation & Assay Strategy
The Y641F mutation shifts substrate specificity from H3K27me3 generation to H3K27me2 accumulation. Therefore, primary screening assays (HTRF/AlphaLISA methyltransferase) should use TarMart EZH2 Y641F SET domain protein with biotinylated H3K27 peptide (aa 21-44) and detect me2 generation. Parallel wild-type EZH2 plates are mandatory to exclude pan-inhibitors. For selectivity profiling, orthogonal methods (ITC, SPR) using high-purity TarMart proteins with low endotoxin (<1 EU/μg) avoid false positives. Cellular validation with TarMart EZH2 Y641F lentivirus in Karpas-422 or SU-DHL-10 cells, followed by H3K27me2 Western blot, confirms target engagement. TarMart also offers PRC2 modular components for flexible complex reconstitution to evaluate allosteric vs. catalytic inhibitors. The gene delivery tools support resistance mechanism studies and PROTAC degrader screening in hard-to-transfect lymphoma cells.